The 17-year single-center experience with the use of azathioprine to maintain remission in ulcerative colitis

Giovanni C. Actis, Maurizio Fadda, Rinaldo Pellicano, Ezio David, Mario Rizzetto, Anna Sapino

Research output: Contribution to journalArticlepeer-review

Abstract

Despite the accumulation of positive data, the role of azathioprine (AZA) in the maintenance of remission of ulcerative colitis is still controversial. We looked at the follow-up of the ulcerative colitis patients who, after responding to either steroids or cyclosporin (CsA), received AZA at our referral center for over a decade. The 39 patients (29 m/10f) were treated between 1991 and 2007. Twenty-five of them had responded to CsA, the remaining 14 to corticosteroids. AZA was usually overlapped with either of the two agents at the initial dose of 2 mg/kg/day. The definitions of remission, relapse, and AZA toxicity followed commonly agreed criteria. The median duration of the AZA treatment was 14 months (

Original languageEnglish
Pages (from-to)362-365
Number of pages4
JournalBiomedicine and Pharmacotherapy
Volume63
Issue number5
DOIs
Publication statusPublished - Jun 2009

Keywords

  • Azathioprine
  • Inflammatory bowel disease
  • Ulcerative colitis

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'The 17-year single-center experience with the use of azathioprine to maintain remission in ulcerative colitis'. Together they form a unique fingerprint.

Cite this